Article Sidebar
Main Article Content
Anticholinergic Burden: A Bibliometric Analysis of Research Trends
Main Article Content
Abstract
Background: Anticholinergic burden is linked to adverse outcomes, including mortality, cardiovascular events, falls, cognitive decline, and dementia, particularly in middle- to older-aged populations. This study aims to provide a comprehensive quantitative analysis of the research landscape surrounding anticholinergic burden using bibliometric methods.
Methods: We searched the last 40 years of databases on the Web of Science platform using various keywords related to anticholinergic burden. Bibliometric analysis and mapping were carried out using VOSviewer software, and the most prominent
research, countries, institutions, authors, journals, co-citations, and keywords were revealed.
Results: A total of 1239 documents published between 1984 and 2024 were identified, with 2020 having the highest number of publications. Seventy-five countries contributed to studies on anticholinergic burden, with the United States leading with 382 publications and 12 023 citations. “Polypharmacy” was the most frequently used keyword in these articles. Over the last 40 years, the most productive author in this field was Sarah H. Hilmer, with 77 publications and 3255 citations.
Conclusion: This study offers researchers a comprehensive summary and analysis of the research on anticholinergic burden. Anticholinergic burden, a multidisciplinary research focus, continues to attract worldwide interest. The cumulative impact of polypharmacy on anticholinergic burden remains a key area of clinical research. Although numerous scales have been developed to assess anticholinergic burden, there remains a significant need for more accurate methods that account for drug dosages, potencies, and individual predispositions, as there is a lack of strong agreement among existing scales.
Cite this article as: Sümbül-Şekerci, B., Pasin, Ö., & Velioğlu, HA. Anticholinergic burden: a bibliometric analysis of research trends. Trends Pharm, 2025, 2, 0004, doi: 10.5152/TrendsPharm.2025.24004.
Article Details
References
1. Taylor-Rowan M, Edwards S, Noel-Storr AH, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5(5):CD013540. [CrossRef]
2. Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604-615. [CrossRef]
3. Hanlon P, Quinn TJ, Gallacher KI, et al. Assessing risks of polypharmacy involving medications with anticholinergic properties. Ann Fam Med. 2020;18(2):148-155. [CrossRef]
4. Mayer T, Haefeli WE, Seidling HM. Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes? Eur J Clin Pharmacol. 2015;71(11):1299-1314. [CrossRef]
5. West T, Pruchnicki MC, Porter K, Emptage R. Evaluation of anticholinergic burden of medications in older adults. J Am Pharm Assoc (2003). 2013;53(5):496-504. [CrossRef]
6. National Institute for Health and Care Excellence [guidelines]. Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers. National Institute for Health and Care Excellence (NICE) Copyright © NICE; 2018.
7. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63(1):85-90. [CrossRef]
8. Egberts A, Moreno-Gonzalez R, Alan H, Ziere G, MattaceRaso FUS. Anticholinergic drug burden and delirium: A systematic review. J Am Med Dir Assoc. 2021;22(1):65-73.e4. [CrossRef]
9. Zheng YB, Shi L, Zhu XM, et al. Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;127:296-306. [CrossRef]
10. Stewart C, Yrjana K, Kishor M, et al. Anticholinergic burden measures predict older People's physical function and quality of life: A systematic review. J Am Med Dir Assoc. 2021;22(1):56-64. [CrossRef]
11. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res. 2021;133:285-296. [CrossRef]
12. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-538. [CrossRef]
13. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-320. [CrossRef]
14. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic Drug Scale as a measure of drugrelated anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-1486. [CrossRef]
15. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513. [CrossRef]
16. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-787. [CrossRef]
17. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-834. [CrossRef]
18. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989-995. [CrossRef]
19. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254-1268. [CrossRef]
20. Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med. 2009;122(12):1142-1149.e1. [CrossRef]
21. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. [CrossRef]
22. Myint PK, Fox C, Kwok CS, Luben RN, Wareham NJ, Khaw KT. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. Age Ageing. 2015;44(2):219-225. [CrossRef]
23. Milton JC, Hill-Smith I, Jackson SHD. Prescribing for older people. Bmj. 2008;336(7644):606-609. [CrossRef]
24. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. [CrossRef]
25. Perdixi E, Cotta Ramusino M, Costa A, et al. Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy. Eur J Ageing. 2024;21(1):11. [CrossRef]
26. López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic drugs in geriatric psychopharmacology. Front Neurosci. 2019;13:1309. [CrossRef]
27. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Réglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 2005;59(2):143-151. [CrossRef]
28. Kersten H, Wyller TB. Anticholinergic drug burden in older people's brain - how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151-159. [CrossRef]
29. Campbell NL, Perkins AJ, Bradt P, et al. Association of anticholinergic burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population. Pharmacotherapy. 2016;36(11):1123-1131. [CrossRef]
30. Chuang YF, Elango P, Gonzalez CE, Thambisetty M. Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults. Alzheimers Dement (N Y). 2017;3(3):471-479. [CrossRef]
31. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477-1483. [CrossRef]
32. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407. [CrossRef]
33. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, HippisleyCox J. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med. 2019;179(8):1084-1093. [CrossRef]
34. Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021;77(2):147-162. [CrossRef]
35. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13(1):17-24. [CrossRef]
36. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People. version 2. Age Ageing; 2015;44(2):213-218. [CrossRef]
37. Naples JG, Marcum ZA, Perera S, et al. Concordance between anticholinergic burden scales. J Am Geriatr Soc. 2015;63(10):2120-2124. [CrossRef]